Drug‐induced systemic lupus erythematosus in a child after 3 years of treatment with carbamazepine. (30th September 2015)

• Record Type: Journal Article
• Authors: Molina‐Ruiz, Ana María; Lasanta, Begoña; Barcia, Ana; Pérez‐Vega, Elisa; Requena, Luis
• Is Part Of: Australasian journal of dermatology. Volume 58:Number 1(2017)
• Page Start: e20
• Page End: e22
• Publication Date: 2015-09-30
• Subjects: carbamazepine -- drug‐induced lupus erythematosus -- paediatric age -- systemic lupus erythematosus; Dermatology -- Periodicals; Dermatology -- Australasia -- Periodicals; 616.5005
• DOI: 10.1111/ajd.12393
• Languages: English
• ISSNs: 0004-8380

Abstract

Abstract: Drug‐induced lupus erythematosus (DILE) is a less severe variant of systemic lupus erythematosus (SLE) that generally resolves within weeks or months after the withdrawal of the implicated drug. DILE is unusual during childhood, with the most frequent age of presentation being at 50–70 years of age. Among different drugs, most commonly procainamide and hydralazine have been implicated as a cause of DILE. However carbamazepine (CBZ) is considered a low‐risk drug and very few cases have been reported in children. We describe the case of CBZ‐induced SLE in a 9‐year‐old girl following 3 years of CBZ therapy. This case report shows that drug‐induced SLE is an important side‐effect to be considered, even after long‐term treatment with CBZ, and also during childhood.